Determining Clinical Study Experiences of Chronic Lymphocytic Leukemia Patients
Part of paid clinical trials in San Francisco, California.
- Sponsor
- Power Life Sciences Inc.
- Study ID
- NCT05899543
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
This research study aims to address the limited understanding of the challenges faced by specific demographic groups of chronic lymphocytic leukemia patients in their participation in clinical trials. This trial will scrutinize the experiences of patients diagnosed with chronic lymphocytic leukemia as they take part in a separate medical intervention clinical trial. The focus will be on tracking the rates of completion and withdrawal among these individuals. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future chronic lymphocytic leukemia patients.
Key Dates
- Start date
- Jul 31, 2024
- Status verified
- Jun 2023
- Primary completion
- Jul 31, 2025
- Completion
- Jul 31, 2026
Study Design
- Enrollment
- 500 participants (estimated)
Primary Outcome Measure
Number of chronic lymphocytic leukemia patients who decide to join in a clinical study [ Time Frame: 3 months ]
Central Contacts
- Michael B Gill4159004227
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Power Life Sciences | San Francisco | California | 94107 | - |
Find similar trials in San Francisco, CA
Related Studies
- A Long-term Extension Study of PCI-32765 (Ibrutinib)PHASE3 · Recruiting · Janssen Research & Development, LLC · Duarte, California
- Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)PHASE1 · Recruiting · Imugene Limited · Gilbert, Arizona
- Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL StudyPHASE3 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell MalignanciesPHASE1/PHASE2 · Recruiting · BeOne Medicines · Birmingham, Alabama